Medical/Pharmaceuticals

First Implant of KingstronBio's ProStyle M® Transcatheter Mitral Valve System Successfully Completed in National Multicenter Confirmatory Study

SHANGHAI, April 8, 2026 /PRNewswire/ -- On March 12, 2026, the first implant of the ProStyle M® Transcatheter Mitral Valve System (ProStyle M®) was successfully completed under pure ultrasound guidance as part of its confirmatory clinical study. The device is independently developed by Kingstron...

2026-04-08 22:22 3301

MALAYSIA HEALTHCARE WEEK KICKS OFF IN DHAKA AS BANGLADESH'S PATIENT MARKET SHIFTS

DHAKA, Bangladesh, April 8, 2026 /PRNewswire/ -- Malaysia Healthcare Week in Dhaka 2026 has officially commenced, bringing Malaysia's healthcare expertise directly to Bangladeshi patients, partners and industry stakeholders as demand for overseas medical treatment continues to rise across the cou...

2026-04-08 21:38 2739

Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors

Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., April 8, 2026 /PRNewswire/ -- Supira Medical, Inc.  (Supira), a clini...

2026-04-08 20:03 3151

"Lactobacillus Rhamnosus L34": A Native Probiotic That Reduces Inflammation in Patients with Chronic Kidney Disease

BANGKOK, April 8, 2026 /PRNewswire/ -- Researchers from the Faculty of Medicine at Chulalongkorn University have identified a native probiotic strain, Lactobacillus rhamnosus L34, that may help reduce inflammation and toxin buildup in pa...

2026-04-08 16:56 2762

Lumonus launches strategic collaboration with leading global cancer center to advance radiation therapy treatment planning

SYDNEY and NEW YORK, April 8, 2026 /PRNewswire/ -- Lumonus, the company behind Lumonus AI, a platform for radiation oncology clinical workflow and automated treatment planning, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), one of the world's premier cancer cen...

2026-04-08 12:13 2935

Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited

* Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products * Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments * Delivers near-term revenue and profitability wi...

2026-04-08 10:21 4319

LBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. Market

NORWALK, Conn., April 8, 2026 /PRNewswire/ -- LBB Specialties (LBBS), a North American distributor ofspecialty chemicals and ingredients providing...

2026-04-08 03:49 2120

Live Cell Observation System Selected for NASA-Supported Project Heading to the International Space Station

Nikon Contributes to Research on the Effects of Microgravity in Drug Discovery TOKYO, April 7, 2026 /PRNewswire/ -- Nikon Corporation (Nikon) is pleased to announce that the live cell observation system developed by Nikon and its U.S.-based subsidiary Nikon Instruments Inc. (NII) has been selecte...

2026-04-07 21:41 3874

TriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta Genomics

TriNetX® will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase® technology for research and patient care innovation CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, April 7, 2026 /PRNewswire/ -- TriNetX, the world's leading federated health data netwo...

2026-04-07 19:32 2567

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-lif...

2026-04-07 19:00 2945

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026). Q1 2026 Highlights * Q1 2026 unaudited ...

2026-04-07 06:57 3195

The 93rd CMEF is set to open in Shanghai, as the world's largest medical device industry exhibition spotlights AI, robotics, and international cooperation

SHANGHAI, April 5, 2026 /PRNewswire/ -- The 93rd China International Medical Equipment Fair (CMEF) will be held from April 9 to 12 at the National Exhibition and Convention Center (NECC) in Shanghai. As the largest global medical device industry chain exhibition, this year's event under the theme...

2026-04-05 20:03 2563

Korea's AI-Driven Healthcare Technologies Take Centre Stage at the upcoming WHX Bangkok 2026

BANGKOK, April 3, 2026 /PRNewswire/ -- WHX Bangkok 2026 organised by Informa Markets is set to be a landmark trade event for showcasing Korea's groundbreaking advancements in AI-driven healthcare and technology. Two leading Korean companies, Korea Body Information Co., Ltd. and maihub, will unvei...

2026-04-03 07:48 2887

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continu...

2026-04-03 04:34 3949

ZEISS advances connected cataract and refractive workflows with new digital, AI and surgical innovations at ASCRS

ZEISS Medical Technology will discuss and showcase latest workflow technologies at ASCRS 2026: * Enhanced Cataract Workflow Efficiency and Patient Outcomes: MicroSurgical Technology irrigation/aspiration handpieces, tips and sleeves, now available for the DORC EVA NEXUSto offer increased surgi...

2026-04-02 21:00 3892

Lupin Completes Acquisition of VISUfarma

MUMBAI, India and LONDON and ROME and ZUG, Switzerland, April 2, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty...

2026-04-02 15:00 3433

Free Tickets Open for 2026 Medtec

SHANGHAI, April 2, 2026 /PRNewswire/ -- Free tickets for 2026 Medtec open on April 1, 2026. Visitors who complete registration before August 31 can enter free of charge. AsAsia's Leading Medical Device Supply Chain Expo — From R&D to Commercial Manufacturing, 2026 Medtec will be held from Septemb...

2026-04-02 09:00 3118

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May...

2026-04-02 06:59 3686

NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient

Pressing issues in oncology, including rising cancer incidences in younger people, plus global opportunities for improving outcomes, were presented alongside cutting-edge research and clinical guidelines updates, during yearly event hosted by the National Comprehensive Cancer Network. ORLANDO, F...

2026-04-02 01:31 2605

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint

SUZHOU, China, April 1, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceu...

2026-04-01 22:44 4480
12345 ... 393